ImmunoBiology Ltd (“ImmBio”) Successfully Closes New Funding Round
ImmunoBiology Ltd ("ImmBio") is pleased to announce that it has closed a new round of finance, raising £3.0m... Read more
Latest News
Sino-UK companies announce TB vaccine partnership deal
ImmunoBiology Ltd, a vaccine development company based at the Babraham Research Campus near Cambridge UK, is pleased to announce the signing of an initial cooperation agreement with LIBP... Read more
University of Nottingham and ImmunoBiology Ltd (“ImmBio”) initiate Clostridium difficile Vaccine Programme, backed by the MRC
The bacterium Clostidium difficile (“C. difficile”) is likely to remain a healthcare issue due to difficulties in preventing infection and its life-threatening consequences... Read more
ImmBio-Led Consortium Releases Promising Data for Meningitis B Vaccine
Preventing meningitis is a major healthcare goal. Infection is rapid but early detection is difficult, by which time the impact can include disability due to damage to the brain, surrounded by the meninges, through to death... Read more
ImmBio Additional Series C Funding Secured To Progress Its Product Portfolio
ImmunoBiology Ltd is pleased to report that it has closed the second part of its C series Round, following successful achievement of a number of milestones.... Read more
ImmunoBiology (ImmBio) Extend Its Collaboration With Eden Biodesign To Develop A New Generation Vaccine For Influenza
Eden Biodesign Ltd. have elected to extend their initial collaboration to develop ImmBio’s innovative influenza vaccine... Read more